Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15391747 | 1.00 | PTGS2 (0.53) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL2471595 | 0.97 | HSD17B10 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL2473862 | 0.97 | HSD17B10 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Aspirin SCHEMBL2472616 | 0.95 | KDM4E (0.62) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Diplosalsalate SCHEMBL3006517 | 0.93 | KDM4E (0.67) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL3807348 | 0.93 | KDM4E (0.67) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Aspirin SCHEMBL28641867 | 0.89 | KDM4E (0.55) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL3810674 | 0.89 | PTGS2 (0.51) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Citric Acid SCHEMBL28465789 | 0.88 | KDM4E (0.44) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL15392163 | 0.87 | PTGS2 (0.49) | PTGS2HSD17B10KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | claimed |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD | 2019-05-16 | — | — | US | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| EP-4245752-A2 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| EP-2610242-A1 | Positively charged water-soluble prodrugs of aspirin | Techfields Biochem Co. Ltd (CN) | 2013-07-03 | — | — | EP | disclosed |
| EP-2610242-A1 | Positively charged water-soluble prodrugs of aspirin | Techfields Biochem Co. Ltd (CN) | 2013-07-03 | — | — | EP | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| EP-2370406-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | Yu, Chongxi (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010065936-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | YU CHONGXI (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| EP-2038251-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ASPIRIN | Techfields Biochem Co. Ltd (CN) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008007171-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ASPIRIN | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGS2 146/4885HSD17B10 275/4885KDM4E 3941/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | PTGS2 100/4885HSD17B10 591/4885KDM4E 4020/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGS2 146/4885HSD17B10 275/4885KDM4E 3941/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGS2 146/4885HSD17B10 275/4885KDM4E 3941/4885 |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | PTGS2 795/4885HSD17B10 541/4885KDM4E 4307/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGS2 146/4885HSD17B10 275/4885KDM4E 3941/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | PTGS2 795/4885HSD17B10 541/4885KDM4E 4307/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | PTGS2 146/4885HSD17B10 275/4885KDM4E 3941/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | PTGS2 445/4885HSD17B10 720/4885KDM4E 2401/4885 |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | CPA3, HCAR2, HRH4 | PTGS2 62/4885HSD17B10 486/4885KDM4E 4181/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | PTGS2 7/4885HSD17B10 454/4885KDM4E 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.